Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA-CD19 CAR-T in Refractory Autoimmune Diseases
NCT06794008Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of GC012 in systemic lupus erythematosus (SLE), inflammatory myopathy (IIM), systemic sclerosis (SSc), Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), IgG4-related disease (IgG4-RD), sponsored by Peking University People's Hospital. Started Dec 2024; status: recruiting.
02
Drugs
GC012
03
Conditions
systemic lupus erythematosus (SLE)inflammatory myopathy (IIM)systemic sclerosis (SSc)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT06794008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06794008.